BTK inhibitors such as tolebrutinib or evobrutinib work about as well as Aubagio at preventing relapses in MS, a review of ...

Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo over weeks ...

Multiple sclerosis (MS) is a condition that disrupts the information pathways that connect your brain and your body. From time to time, the symptoms of MS can unexpectedly worsen. When symptoms ...

Multiple sclerosis (MS) is a chronic disease of the central nervous system. MS disrupts the flow of information between the ...

The quest to understand and slow disease progression in multiple sclerosis (MS) continued in 2024, with research revealing possible new treatments and furthering knowledge about the disease course.

Prenatal and early life sun exposure was associated with lower risk for relapse in children with pediatric-onset multiple sclerosis (MS), a new prospective cohort study showed. At least 30 minutes of ...

A blood test might predict when multiple sclerosis patients are about to suffer a relapse in their symptoms, a new study says. Blood levels of a protein called neurofilament light chain rise ...

Disability progression independent of relapse activity (PIRA) -- sometimes referred to as silent progression -- is a key integrating concept in the contemporary view of multiple sclerosis (MS). "The ...

Panelists discuss how progression independent of relapse activity (PIRA) represents a distinct pathological process involving smoldering inflammation and neurodegeneration that drives disability in ...

Cerebrospinal fluid (CSF)-based molecular tests can reliably distinguish multiple sclerosis (MS) from other neurological conditions, according to a new study that analyzed cryopreserved CSF samples ...

Specialists in multiple sclerosis will gather in San Diego for ACTRIMS Forum 2026, Feb. 5-7, where the theme will be “MS at a ...